文献速递血液净化与透析

评估功能不良动静脉内瘘的干预率:IN.PACT AV Access 试验的事后分析

Evaluating Intervention Rates for Dysfunctional Arteriovenous Fistulas: Post-hoc Analysis of the IN.PACT AV Access Trial.
PubMed 文献 · Am J Kidney Dis · 2025-08-13

该研究为 IN.PACT AV Access 随机临床试验的事后分析,纳入 330 例已成熟动静脉内瘘的成人血液透析患者,比较药物涂层球囊(DCB)与标准球囊经皮腔内血管成形术(PTA)的干预率。结果显示,DCB 组维持通路回路通畅的每 AVF 年干预次数为 1.39,标准 PTA 组为 1.66(率差 -0.28,95%CI -0.47 至 -0.08,P=0.01);两组均达到 KDOQI 2019 指南 ≤3 次/年的目标。

要点

  • DCB 组每 AVF 年干预次数 1.39,标准 PTA 组 1.66,率差 -0.28(95%CI -0.47 至 -0.08,P=0.01)。
  • 通路回路血栓形成率 DCB 组 0.041,标准 PTA 组 0.069,率差 -0.028(95%CI -0.065 至 0.0082,P=0.1)。
  • 两组均达到 KDOQI 2019 指南 ≤3 次经皮或外科干预/年的目标。

核心结论

  • DCB 组和标准 PTA 组均达到 KDOQI 目标,即每年≤3 次经皮或外科干预以维持 AVF 通畅。
  • 与标准 PTA 相比,使用 DCB 在 36 个月内减少了维持通畅所需的再干预需求和血栓形成率。

研究设计与样本

  • IN.PACT AV Access 随机临床试验的事后分析。
  • 纳入 2017 年 4 月至 2018 年 5 月在美国、日本和新西兰入组的已成熟 AVF 且存在新发或非支架内再狭窄病变的成人门诊血液透析患者。
  • 患者随机接受 IN.PACT AV DCB 的 PTA 或标准球囊 PTA。
  • 共 330 例参与者随机化,其中 133 例完成 3 年随访。

主要发现

  • 至 36 个月维持通路回路通畅的每 AVF 年干预次数:DCB 组 1.39,标准 PTA 组 1.66(率差 -0.28,95%CI -0.47 至 -0.08,P=0.01)。
  • 通路回路血栓形成率:DCB 组 0.041,标准 PTA 组 0.069(率差 -0.028,95%CI -0.065 至 0.0082,P=0.1)。

关键数值与推荐

  • KDOQI 2019 血管通路指南目标:每年≤3 次经皮或外科干预以维持 AVF 通畅。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 排除了既往血栓形成的 AVF。
  • 36 个月时样本量小。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: A key target of the Kidney Disease Outcomes Quality Initiative (KDOQI) 2019 vascular access guidelines is to have ≤3 percutaneous or surgical interventions per year to maintain arteriovenous fistula (AVF) patency. We hypothesized that the number of interventions to maintain long-term AVF patency as conducted in a rigorous clinical trial could be adequately documented and compared against KDOQI targets and that the use of drug-coated balloons (DCB) could reduce the rate of thrombosis and interventions to maintain AVF patency more than the standard percutaneous transluminal angioplasty (PTA) with an uncoated balloon. STUDY DESIGN: Post-hoc analysis of the IN.PACT AV Access randomized clinical trial. SETTING & PARTICIPANTS: Outpatient adult hemodialysis patients with previously matured AVFs that had de novo or nonstented restenotic lesions enrolled between April 2017 and May 2018 in the United States, Japan, and New Zealand. EXPOSURE: Patients were randomized to receive PTA with the IN.PACT AV DCB or a standard balloon. OUTCOME: Rate of interventions to maintain access target lesion and access circuit patency and rate of access circuit thrombosis were calculated in both intervention groups and compared against the KDOQI 2019 guideline targets. RESULTS: Of the 330 participants randomized, 133 patients completed their 3-year visits. The number of interventions per AVF-year to maintain access circuit patency through 36 months was 1.39 for the DCB group and 1.66 for the standard PTA group (rate difference, -0.28 [95% CI, -0.47 to -0.08], P = 0.01). The access circuit thrombosis rate was 0.041 in the DCB group and 0.069 in the standard PTA group (rate difference, -0.028 [95% CI, -0.065 to 0.0082], P = 0.1). LIMITATIONS: Exclusion of AVF with prior thrombosis and small sample size at 36 months. CONCLUSIONS: Both DCB and standard PTA groups met the KDOQI targets of ≤3 percutaneous or surgical interventions per year to maintain AVF patency. The need for reinterventions to maintain patency and thrombosis rate was reduced with the use of DCB compared with standard PTA through 36 months.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Gopal A, Haruguchi H, Holden A, et al. Evaluating Intervention Rates for Dysfunctional Arteriovenous Fistulas: Post-hoc Analysis of the IN.PACT AV Access Trial. Am J Kidney Dis. 2025. PMID: 40816624. doi:10.1053/j.ajkd.2025.05.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。